Last updated on September 2018

Targeting Risk Interventions and Metformin for Atrial Fibrillation (TRIM-AF)


Brief description of study

The purpose of this study is to perform a prospective, randomized study for the reduction of atrial fibrillation (AF) burden and progression, targeting metabolic upstream therapies. The study aims to determine if metformin and/or lifestyle/risk factor modifications reduce AF burden and progression. A secondary aim will attempt to determine clinical, genomic, and biomarker predictors of AF progression that can be used to personalize upstream therapies. This is a prospective randomized open-label blinded endpoint (PROBE) 2x2 factorial study of metformin extended release up to 750 mg twice daily and lifestyle and risk factor modification (LRFM) in patients with implanted pacemakers or defibrillators with atrial leads and at least 1 5 minute episode of AF over the prior 3 months.

Clinical Study Identifier: NCT03603912

Contact Investigators or Research Sites near you

Start Over

Mina K Chung, MD

Cleveland Clinic
Cleveland, OH United States
  Connect »